ArticleOxidative medicine and cellular longevity2021
The Antioxidant Enzyme PON1: A Potential Prognostic Predictor of Acute Ischemic Stroke.
Article in Oxidative medicine and cellular longevity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Serum ICAM-1 as a Predictor of Prognosis in Patients with Acute Ischemic Stroke.BioMed research international · 2021Trial
- Unveiling the Neuroprotective Effect of Paraoxonase 1 in Neurodegenerative Diseases Focusing on Alzheimer's Disease.Molecular neurobiology · 2025Review
- Serum Paraoxonase-1 (PON-1) in Dogs: Frequency of Decreased Values in Clinical Practice and Prognostic Significance.Veterinary sciences · 2025Article
- Multiple facets of HDLs as modifiable risk factors in stroke-the good, the bad, and the ugly.Journal of lipid research · 2025Review
- The Role of Polyphenols in Modulating PON1 Activity Regarding Endothelial Dysfunction and Atherosclerosis.International journal of molecular sciences · 2024Review
- Paraoxonases at the Heart of Neurological Disorders.International journal of molecular sciences · 2023Review
- In Mild and Moderate Acute Ischemic Stroke, Increased Lipid Peroxidation and Lowered Antioxidant Defenses Are Strongly Associated with Disabilities and Final Stroke Core Volume.Antioxidants (Basel, Switzerland) · 2023Article
- Higher serum β2-microglobulin is a predictive biomarker for cognitive impairment in spinal cord injury.PeerJ · 2023Article
- Clinicoradiological evaluation of oxidative stress activity in acute cerebral infarction in the first 24 h and the qualitative importance of dysfunctional HDL in stroke.Turkish journal of medical sciences · 2022Article
- A Nomogram model for predicting the occurrence of no-reflow phenomenon after percutaneous coronary intervention using the lncRNAJournal of thoracic disease · 2022Article
- Traditional Chinese medicine promotes the control and treatment of dementia.Frontiers in pharmacology · 2022Review
- Netrin-1: A Serum Marker Predicting Cognitive Impairment after Spinal Cord Injury.Disease markers · 2022Article
- Effects of Early Acupuncture Combined with Rehabilitation Training on Limb Function and Nerve Injury Rehabilitation in Elderly Patients with Stroke: Based on a Retrospective Cohort Study.BioMed research international · 2022Article
- Nogo-A Is a Potential Prognostic Marker for Spinal Cord Injury.Disease markers · 2022Article
- Identification of circulating immune landscape in ischemic stroke based on bioinformatics methods.Frontiers in genetics · 2022Article
- Salivary Biomarkers of Oxidative Stress and Inflammation in Stroke Patients: From Basic Research to Clinical Practice.Oxidative medicine and cellular longevity · 2021Review
- Serum Neuropeptide Y: A Potential Prognostic Marker of Intracerebral Hemorrhage.Disease markers · 2021Article
- The Prognostic Value of Serum Uric Acid in Hospitalized Patients with Acute Cerebral Infarction.Disease markers · 2021Article
- VEGF Family Gene Expression as Prognostic Biomarkers for Alzheimer's Disease and Primary Liver Cancer.Computational and mathematical methods in medicine · 2021Article
- Serum Galectin-3 as a Potential Predictive Biomarker Is Associated with Poststroke Cognitive Impairment.Oxidative medicine and cellular longevity · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveParaoxonase 1 (PON1) is an antioxidant enzyme, which has been proved to be involved in the pathophysiological process of oxidative stress and various neurological diseases in recent years. Although reduced PON1 activity has been reported in patients with acute ischemic stroke (AIS), the prognostic value of PON1 in AIS has not been clearly established. The purpose of this study was to determine whether the baseline serum PON1 activity level is related to the functional outcome of AIS patients.
methodsFrom July 2017 to June 2020, AIS patients within 3 days of symptom onset were continuously prospectively included in the study. On admission, clinical and laboratory data were recorded, and serum PON1 activity was tested. The National Institute of Health Stroke Scale (NIHSS) score was used to evaluate the initial neurologic deficit at admission, and the modified Rankin scale (mRS) was used to evaluate the functional outcome at 3 months. A multiple logistic regression model was used to analyze the relationship between the baseline PON1 activity level and the prognosis of AIS.
resultsA total of 336 AIS patients were finally included in this study. The serum PON1 activity of AIS patients with good outcomes was significantly higher than that of patients with poor outcomes (193.4 ± 16.3 U/mL vs. 127.2 ± 14.9 U/mL,
conclusionsThis study suggests that the serum PON1 activity may be an independent predictor of the functional outcome of AIS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.